We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
GlycoMimetics Inc | NASDAQ:GLYC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.14 | -7.78% | 1.66 | 1.62 | 1.66 | 1.93 | 1.62 | 1.80 | 982,228 | 00:55:44 |
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will present at four investor conferences during the month of March, including:
30th Annual ROTH ConferenceMarch 11 – 14, 2018, The Ritz Carlton, Dana Point, CACFO Brian Hahn will present on March 12 at 3:30 p.m. PT.
Cowen 38th Annual Health Care ConferenceMarch 11 – 14, 2018, Copley Place Marriott, Boston, MACEO Rachel King will present on March 14 at 9:20 a.m. ET.
BioCentury: 25th Annual Future Leaders in the BioTech IndustryMarch 23, 2018, Millennium Broadway Hotel & Conference Center, New York, NYMrs. King will present in room 311 at 2:30 p.m. ET.
Needham & Company’s 17th Annual HealthCare ConferenceMarch 27 – 28, 2018, Westin Grand Central Hotel, New York, NYMrs. King will present on March 27 at 8:00 a.m. ET.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is currently being evaluated in a Phase 1 clinical trial for the treatment of multiple myeloma. The FDA granted GMI-1271 Breakthrough Therapy designation for the treatment of adult AML patients with relapsed/refractory disease. GlycoMimetics has also recently initiated a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180307005331/en/
For GlycoMimetics, Inc.Investors:Shari Annes, 650-888-0902sannes@annesassociates.comorMedia:Jamie Lacey-Moreira, 410-299-3310jamielacey@presscommpr.com
1 Year GlycoMimetics Chart |
1 Month GlycoMimetics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions